<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39403104</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>16</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2667-646X</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Infectious diseases &amp; clinical microbiology</Title><ISOAbbreviation>Infect Dis Clin Microbiol</ISOAbbreviation></Journal><ArticleTitle>A New Biomarker Copeptin in Determining Disease Severity in COVID-19.</ArticleTitle><Pagination><StartPage>225</StartPage><EndPage>232</EndPage><MedlinePgn>225-232</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.36519/idcm.2024.324</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">Copeptin is released from the posterior pituitary gland into systemic circulation in response to various stimuli, including stress. We aimed to evaluate the role of copeptin in determining the severity of the disease in patients with COVID-19.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="UNASSIGNED">The study was conducted prospectively in two centers between June 1, 2022, and October 1, 2022. Severe and mild-moderate COVID-19 patients were compared in terms of clinical, laboratory and imaging findings, and serum copeptin levels at hospitalization.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A total of 90 patients were included in the study; 45 patients were in severe disease groups. Dyspnea, loss of appetite, and loss of smell were significantly more common in the severe disease group (<i>p</i>&lt;0.001, <i>p</i>=0.025, and <i>p</i>&lt;0.001, respectively). Among the tomography findings, the consolidation frequency was similar in both groups (<i>p</i>=0.259). C-reactive protein (CRP), D-dimer, ferritin, lactate dehydrogenase (LDH), procalcitonin, troponin and copeptin levels were higher in the severe group (<i>p</i>&lt;0.05); hemoglobin, total protein and vitamin D levels were lower (<i>p</i>=0.05). The area under the curve (AUC) values for severe disease were 0.643 for copeptin (<i>p</i>=0.019), 0.656 for CRP (<i>p</i>=0.011), 0.684 for procalcitonin (<i>p</i>=0.004), 0.657 for ferritin (<i>p</i>=0.01), 0.72 for D-dimer (<i>p</i>=0), 0.688 for troponin (<i>p</i>=0.002), and 0.672 for age (<i>p</i>=0.005).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">In our study, copeptin was identified as a new prognostic biomarker indicating the severity of the disease in patients with COVID-19.</AbstractText><CopyrightInformation>Copyright © 2024 Infectious Diseases and Clinical Microbiology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Korkmaz</LastName><ForeName>Pınar</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-5035-5895</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases and Microbiology, Kütahya Health Sciences University School of Medicine, Kütahya, Türkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mıstanoğlu-Özatağ</LastName><ForeName>Duru</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-0005-192x</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases and Microbiology, Kütahya Health Sciences University School of Medicine, Kütahya, Türkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keskin</LastName><ForeName>Havva</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-1794-4473</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Ankara University School of Medicine, Ankara, Türkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koçak</LastName><ForeName>Havva</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-7147-0179</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry, Kütahya Health Sciences University School of Medicine, Kütahya, Türkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uçar</LastName><ForeName>Selcen</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-2326-5565</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Sancaktepe Şehit Prof. Dr. İlhan Varank Training and Research Hospital, İstanbul, Türkiye.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Turkey</Country><MedlineTA>Infect Dis Clin Microbiol</MedlineTA><NlmUniqueID>9918680988406676</NlmUniqueID><ISSNLinking>2667-646X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">copeptin</Keyword><Keyword MajorTopicYN="N">disease</Keyword><Keyword MajorTopicYN="N">prognosis</Keyword><Keyword MajorTopicYN="N">severity</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>10</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>4</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39403104</ArticleId><ArticleId IdType="pmc">PMC11472025</ArticleId><ArticleId IdType="doi">10.36519/idcm.2024.324</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Elshafei A, Khidr EG, El-Husseiny AA, Gomaa MH. RAAS, ACE2 and COVID-19; a mechanistic review. Saudi J Biol Sci. 2021;28(11):6465–6470. doi: 10.1016/j.sjbs.2021.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sjbs.2021.07.003</ArticleId><ArticleId IdType="pmc">PMC8270731</ArticleId><ArticleId IdType="pubmed">34305426</ArticleId></ArticleIdList></Reference><Reference><Citation>Lone SA, Ahmad A. COVID-19 pandemic – an African perspective. Emerg Microbes Infect. 2020;9(1):1300–1308. doi: 10.1080/22221751.2020.1775132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2020.1775132</ArticleId><ArticleId IdType="pmc">PMC7473237</ArticleId><ArticleId IdType="pubmed">32458760</ArticleId></ArticleIdList></Reference><Reference><Citation>Pal M, Berhanu G, Desalegn C, Kandi V. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): An Update. Cureus. 2020;12(3):e7423. doi: 10.7759/cureus.7423.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.7423</ArticleId><ArticleId IdType="pmc">PMC7182166</ArticleId><ArticleId IdType="pubmed">32337143</ArticleId></ArticleIdList></Reference><Reference><Citation>İn E, Kuluöztürk M, Telo S, Toraman ZA, Karabulut E. Can copeptin predict the severity of coronavirus disease 2019 infection? Rev Assoc Med Bras (1992) 2021;67(8):1137–1142. doi: 10.1590/1806-9282.20210525.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/1806-9282.20210525</ArticleId><ArticleId IdType="pubmed">34669859</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufmann CC, Ahmed A, Kassem M, Freynhofer MK, Jäger B, Aicher G, et al. Improvement of outcome prediction of hospitalized patients with COVID-19 by a dual marker strategy using high-sensitive cardiac troponin I and copeptin. Clin Res Cardiol. 2022;111(3):343–354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8592075</ArticleId><ArticleId IdType="pubmed">34782921</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregoriano C, Molitor A, Haag E, Kutz A, Koch D, Haubitz S, et al. Activation of vasopressin system during COVID-19 is associated with adverse clinical outcomes: an observational study. J Endocr Soc. 2021;5(6):bvab045. doi: 10.1210/jendso/bvab045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jendso/bvab045</ArticleId><ArticleId IdType="pmc">PMC7989362</ArticleId><ArticleId IdType="pubmed">34056499</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammad R, Elshafei A, Khidr EG, El-Husseiny AA, Gomaa MH, Kotb HG, et al. Copeptin: a neuroendocrine biomarker of COVID-19 severity. Biomark Med. 2022;16(8):589–597. doi: 10.2217/bmm-2021-1100.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/bmm-2021-1100</ArticleId><ArticleId IdType="pmc">PMC8966690</ArticleId><ArticleId IdType="pubmed">35350852</ArticleId></ArticleIdList></Reference><Reference><Citation>Christ-Crain M, Fenske W. Copeptin in the diagnosis of vasopressin-dependent disorders of fluid homeostasis. Nat Rev Endocrinol. 2016;12(3):168–176. doi: 10.1038/nrendo.2015.224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrendo.2015.224</ArticleId><ArticleId IdType="pubmed">26794439</ArticleId></ArticleIdList></Reference><Reference><Citation>Katan M, Morgenthaler N, Widmer I, Puder JJ, König C, Müller B, et al. Copeptin, a stable peptide derived from the vasopressin precursor, correlates with the individual stress level. Neuro Endocrinol Lett. 2008;29(3):341–346.</Citation><ArticleIdList><ArticleId IdType="pubmed">18580851</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobsa L, Edozien KC. Copeptin and its potential role in diagnosis and prognosis of various diseases. Biochem Med (Zagreb) 2013;23(2):172–190. doi: 10.11613/bm.2013.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.11613/bm.2013.021</ArticleId><ArticleId IdType="pmc">PMC3900057</ArticleId><ArticleId IdType="pubmed">23894863</ArticleId></ArticleIdList></Reference><Reference><Citation>Muthyala A, Sasidharan S, John KJ, Lal A, Mishra AK. Utility of cardiac bioenzymes in predicting cardiovascular outcomes in SARS-CoV-2. World J Virol. 2022;11(5):375–390. doi: 10.5501/wjv.v11.i5.375.</Citation><ArticleIdList><ArticleId IdType="doi">10.5501/wjv.v11.i5.375</ArticleId><ArticleId IdType="pmc">PMC9523328</ArticleId><ArticleId IdType="pubmed">36188743</ArticleId></ArticleIdList></Reference><Reference><Citation>Indirli R, Bandera A, Valenti L, Ceriotti F, Di Modugno A, Tettamanti M, et al. COVID-19 Network Working Group. Prognostic value of copeptin and mid-regional proadrenomedullin in COVID-19-hospitalized patients. Eur J Clin Invest. 2022;52(5):e13753. doi: 10.1111/eci.13753.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/eci.13753</ArticleId><ArticleId IdType="pmc">PMC9111431</ArticleId><ArticleId IdType="pubmed">35128648</ArticleId></ArticleIdList></Reference><Reference><Citation>Christ-Crain M. Vasopressin and copeptin in health and disease. Rev Endocr Metab Disord. 2019;20(3):283–294. doi: 10.1007/s11154-019-09509-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11154-019-09509-9</ArticleId><ArticleId IdType="pubmed">31656992</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, Dong G, Zhao X, Wang M, Li CS. Prognostic significance of hypothalamic-pituitary-adrenal axis hormones in early sepsis: a study performed in the emergency department. Intensive Care Med. 2014;40(10):1499–1508. doi: 10.1007/s00134-014-3468-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-014-3468-4</ArticleId><ArticleId IdType="pubmed">25223852</ArticleId></ArticleIdList></Reference><Reference><Citation>Seligman R, Papassotiriou J, Morgenthaler NG, Meisner M, Teixeira PJ. Copeptin, a novel prognostic biomarker in ventilator-associated pneumonia. Crit Care. 2008;12(1):R11. doi: 10.1186/cc6780.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc6780</ArticleId><ArticleId IdType="pmc">PMC2374597</ArticleId><ArticleId IdType="pubmed">18252006</ArticleId></ArticleIdList></Reference><Reference><Citation>Müller B, Morgenthaler N, Stolz D, Schuetz P, Müller C, Bingisser R, et al. Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infections. Eur J Clin Invest. 2007;37(2):145–152. doi: 10.1111/j.1365-2362.2007.01762.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2362.2007.01762.x</ArticleId><ArticleId IdType="pubmed">17217381</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 (SARS-CoV-2 Enfeksiyonu): Erişkin hasta tedavisi. Ankara: T.C. Sağlık Bakanlığı.  [October 29, 2023]. 
https://covid19.saglik.gov.tr/Eklenti/43095/0/covid-19rehberieriskinhastayonetimivetedavi-12042022pdf.pdf
</Citation></Reference><Reference><Citation>Christ-Crain M, Fenske WK. Copeptin in the differential diagnosis of hypotonic polyuria. J Endocrinol Invest. 2020;43(1):21–30. doi: 10.1007/s40618-019-01087-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40618-019-01087-6</ArticleId><ArticleId IdType="pubmed">31368050</ArticleId></ArticleIdList></Reference><Reference><Citation>Demerdash HM, Omar E, Arida E. Evaluation of copeptin and psychological stress among healthcare providers during COVID-19 pandemic. Egyptian J Anaes. 2021;37(1):227–233. doi: 10.1080/11101849.2021.1925442.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/11101849.2021.1925442</ArticleId></ArticleIdList></Reference><Reference><Citation>Yousaf Z, Al-Shokri SD, Al-Soub H, Mohamed MFH. COVID-19-associated SIADH: a clue in the times of pandemic! Am J Physiol Endocrinol Metab. 2020;318(6):E882-5. doi: 10.1152/ajpendo.00178.2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpendo.00178.2020</ArticleId><ArticleId IdType="pmc">PMC7276977</ArticleId><ArticleId IdType="pubmed">32396497</ArticleId></ArticleIdList></Reference><Reference><Citation>Koch A, Yagmur E, Hoss A, Buendgens L, Herbers U, Weiskirchen R, et al. Clinical relevance of copeptin plasma levels as a biomarker of disease severity and mortality in critically ill patients. J Clin Lab Anal. 2018;32(9):e22614. doi: 10.1002/jcla.22614.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcla.22614</ArticleId><ArticleId IdType="pmc">PMC6817249</ArticleId><ArticleId IdType="pubmed">29974524</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ ; HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–1034. doi: 10.1016/S0140-6736(20)30628-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30628-0</ArticleId><ArticleId IdType="pmc">PMC7270045</ArticleId><ArticleId IdType="pubmed">32192578</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruzzenenti G, Maloberti A, Giani V, Biolcati M, Leidi F, Monticelli M, et al. Covid-19 Niguarda Working Group. Covid and cardiovascular diseases: direct and indirect damages and future perspective. High Blood Press Cardiovasc Prev. 2021;28(5):439–445. doi: 10.1007/s40292-021-00464-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40292-021-00464-8</ArticleId><ArticleId IdType="pmc">PMC8233573</ArticleId><ArticleId IdType="pubmed">34173942</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuluöztürk M, İn E, Telo S, Karabulut E, Geçkil AA. Efficacy of copeptin in distinguishing COVID-19 pneumonia from community-acquired pneumonia. J Med Virol. 2021;93(5):3113–3121. doi: 10.1002/jmv.26870.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26870</ArticleId><ArticleId IdType="pmc">PMC8013559</ArticleId><ArticleId IdType="pubmed">33570194</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>